Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 225

1.

Epidermal growth factor receptor cooperates with Src family kinases in acquired resistance to cetuximab.

Wheeler DL, Iida M, Kruser TJ, Nechrebecki MM, Dunn EF, Armstrong EA, Huang S, Harari PM.

Cancer Biol Ther. 2009 Apr;8(8):696-703. Epub 2009 Apr 22.

2.

Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy.

Iida M, Brand TM, Starr MM, Huppert EJ, Luthar N, Bahrar H, Coan JP, Pearson HE, Salgia R, Wheeler DL.

Mol Cancer. 2014 Oct 24;13:242. doi: 10.1186/1476-4598-13-242.

3.

Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.

Dunn EF, Iida M, Myers RA, Campbell DA, Hintz KA, Armstrong EA, Li C, Wheeler DL.

Oncogene. 2011 Feb 3;30(5):561-74. doi: 10.1038/onc.2010.430. Epub 2010 Oct 18.

4.

Effects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinib-resistant non-small cell lung cancer cells with acquired MET amplification.

Yoshida T, Okamoto I, Okamoto W, Hatashita E, Yamada Y, Kuwata K, Nishio K, Fukuoka M, Jänne PA, Nakagawa K.

Cancer Sci. 2010 Jan;101(1):167-72. doi: 10.1111/j.1349-7006.2009.01368.x. Epub 2009 Sep 14.

5.
6.
7.

Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.

Huang S, Armstrong EA, Benavente S, Chinnaiyan P, Harari PM.

Cancer Res. 2004 Aug 1;64(15):5355-62.

8.

Erlotinib is a viable treatment for tumors with acquired resistance to cetuximab.

Brand TM, Dunn EF, Iida M, Myers RA, Kostopoulos KT, Li C, Peet CR, Wheeler DL.

Cancer Biol Ther. 2011 Sep 1;12(5):436-46. Epub 2011 Sep 1.

9.

The receptor tyrosine kinase AXL mediates nuclear translocation of the epidermal growth factor receptor.

Brand TM, Iida M, Corrigan KL, Braverman CM, Coan JP, Flanigan BG, Stein AP, Salgia R, Rolff J, Kimple RJ, Wheeler DL.

Sci Signal. 2017 Jan 3;10(460). pii: eaag1064. doi: 10.1126/scisignal.aag1064.

PMID:
28049763
10.

Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members.

Wheeler DL, Huang S, Kruser TJ, Nechrebecki MM, Armstrong EA, Benavente S, Gondi V, Hsu KT, Harari PM.

Oncogene. 2008 Jun 26;27(28):3944-56. doi: 10.1038/onc.2008.19. Epub 2008 Feb 25.

11.

Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status.

Formisano L, D'Amato V, Servetto A, Brillante S, Raimondo L, Di Mauro C, Marciano R, Orsini RC, Cosconati S, Randazzo A, Parsons SJ, Montuori N, Veneziani BM, De Placido S, Rosa R, Bianco R.

Oncotarget. 2015 Sep 22;6(28):26090-103. doi: 10.18632/oncotarget.4636.

12.

Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy.

Thomson S, Petti F, Sujka-Kwok I, Epstein D, Haley JD.

Clin Exp Metastasis. 2008;25(8):843-54. doi: 10.1007/s10585-008-9200-4. Epub 2008 Aug 12.

PMID:
18696232
13.

The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer.

Raben D, Helfrich B, Chan DC, Ciardiello F, Zhao L, Franklin W, Barón AE, Zeng C, Johnson TK, Bunn PA Jr.

Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):795-805.

14.

Yes and Lyn play a role in nuclear translocation of the epidermal growth factor receptor.

Iida M, Brand TM, Campbell DA, Li C, Wheeler DL.

Oncogene. 2013 Feb 7;32(6):759-67. doi: 10.1038/onc.2012.90. Epub 2012 Mar 19.

15.

Nuclear EGFR contributes to acquired resistance to cetuximab.

Li C, Iida M, Dunn EF, Ghia AJ, Wheeler DL.

Oncogene. 2009 Oct 29;28(43):3801-13. doi: 10.1038/onc.2009.234. Epub 2009 Aug 17.

16.

Matuzumab and cetuximab activate the epidermal growth factor receptor but fail to trigger downstream signaling by Akt or Erk.

Yoshida T, Okamoto I, Okabe T, Iwasa T, Satoh T, Nishio K, Fukuoka M, Nakagawa K.

Int J Cancer. 2008 Apr 1;122(7):1530-8.

17.
18.

Dacomitinib, an irreversible Pan-ErbB inhibitor significantly abrogates growth in head and neck cancer models that exhibit low response to cetuximab.

Ather F, Hamidi H, Fejzo MS, Letrent S, Finn RS, Kabbinavar F, Head C, Wong SG.

PLoS One. 2013;8(2):e56112. doi: 10.1371/journal.pone.0056112. Epub 2013 Feb 6.

19.

An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models.

Xia W, Petricoin EF 3rd, Zhao S, Liu L, Osada T, Cheng Q, Wulfkuhle JD, Gwin WR, Yang X, Gallagher RI, Bacus S, Lyerly HK, Spector NL.

Breast Cancer Res. 2013;15(5):R85.

20.

Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer.

Gadgeel SM, Wozniak A.

Clin Lung Cancer. 2013 Jul;14(4):322-32. doi: 10.1016/j.cllc.2012.12.001. Epub 2013 Jan 16. Review.

PMID:
23332287

Supplemental Content

Support Center